NewTimeSpace News: On 26 August 2026, PATEO (02889.HK) announced that it has entered the global supply system of a leading international automotive group for the first time, securing dual-brand designations covering the global models of a premium luxury brand and the export models of a mid-to-high-end brand, involving overseas markets including Europe, the Middle East and South America; the Company will provide high-end intelligent cockpit domain controllers and AI in-vehicle interaction systems based on Qualcomm's fourth-generation Snapdragon 8295 platform.
NewTimeSpace News: On 26 August 2026, CANSINOBIO (06185.HK) announced that its mRNA platform is advancing the development of therapeutic biological products and delivery systems, with mRNA vaccines for glioblastoma, rhabdomyosarcoma, cervical cancer and In Vivo CAR-related therapies all at an early stage; its subsidiary CanSino Shanghai has entered into a strategic cooperation framework agreement with Depushi (Hangzhou) Biotechnology for the co-development of mRNA personalized therapeutic tumor vaccines.
NewTimeSpace News: On 26 August 2026, CSPC PHARMA (01093.HK) announced that its first-in-class PD-1/IL-15 bispecific fusion protein SYS6090 (JMT108) has been granted Fast Track designation by the US FDA for the treatment of MSS/pMMR metastatic colorectal cancer (mCRC) that has progressed after prior standard systemic therapy; the product has the potential to selectively remodel the immunologically "cold" tumor microenvironment and activate exhausted effector cells.
NewTimeSpace News: On 26 August 2026, PRUDENTIAL (02378.HK) announced that its subsidiary PCHL proposes to sell up to 2.0% of its shareholding in IPAMC through the open market, expected to take place on 27 August 2026, to assist IPAMC in meeting India's minimum public shareholding requirement (15% within five years after the IPO); upon completion, PCHL will retain a 32.6% stake in IPAMC with its governance rights unchanged.
NewTimeSpace News: On 26 August 2026, CSPC PHARMA (01093.HK) announced that its EGFR-targeting ADC SYS6010 has met the pre-specified primary endpoint of progression-free survival (PFS) in the Phase III study SYNSTAR-01 in EGFR-mutant locally advanced or metastatic NSCLC after EGFR TKI failure, as assessed by the IDMC, with PFS significantly superior to platinum-based chemotherapy with statistical significance and clinical meaningfulness, an observed trend of overall survival benefit, and a favorable overall safety profile.
NewTimeSpace News: On 26 August 2026, CHINA FOODS (00506.HK) announced that its senior management (including executive directors), based on their confidence in the Company's business prospects and long-term investment value, plans to purchase an aggregate of 1,000,000 shares of the Company in open market transactions within two months from the date of the announcement; the purchases will strictly comply with the Listing Rules and the Company's securities trading policy, and the plan is subject to risks of being unable or partially unable to be implemented.
NewTimeSpace News: August 26, 2026, HANSOH PHARMA(03692.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 8.3 billion, increased by 11.71% YoY.
On August 26, the three major Hong Kong indices rose collectively, with the Hang Seng Index up 0.56% to 25,652.97 points, the Hang Seng TECH Index up 0.82%, and turnover at HKD 254.824 billion. Copper-mining stocks led the gains, with JIANGXI COPPER up 9.92% as London copper hit a record closing high. Most China-concept brokerage stocks rose, with CICC up 8.25%. Quality-earnings stocks performed strongly, with INNOVENT BIO up 9.69% and ANTA SPORTS up 9.53%. Oil & gas stocks came under broad pressure. Southbound capital recorded a net buy of HKD 6.453 billion. SPDB International forecast the HSI quarterly review to trigger HKD 38.6 billion in fund flows, with 54 stocks likely to enter Stock Connect in September; Jack Ma boosted Alibaba stake by over HKD 600 million in consecutive days, and STAR SPORTS MED was included in the Hang Seng Composite Index.
NewTimeSpace News: On 26 August 2026, GBA HOLDINGS (00261.HK) announced the completion of a placing of 46.56 million new shares at HKD 0.20 each, raising approximately HKD 8.66 million net (approximately 14.05% of the enlarged share capital), with proceeds earmarked for expanding its financial and corporate advisory businesses and general working capital.
NewTimeSpace News: On 26 August 2026, C FIN SERVICES (00605.HK) announced that its subsidiary Shenzhen Lingda Microfinance granted a loan of RMB 10 million for six months at 24% per annum, secured by two commercial properties in Shenzhen Futian.
NewTimeSpace News: On 26 August 2026, SUNHO BIO-B (02898.HK) announced that, as the publication of the 2025 annual results is still in progress, the 2026 interim results will be delayed beyond the 31 August 2026 deadline, with the interim report also likely to be delayed; the Company's shares have been suspended since 1 April 2026 and will remain suspended until all resumption guidance has been fulfilled.
NewTimeSpace News: On 26 August 2026, CENTURY GINWA (00162.HK) announced the appointment of Lv Haiying as independent non-executive director and remuneration committee chairman (annual fee of RMB 100,000) and Feng Ju as independent non-executive director and audit committee member (annual fee of HKD 120,000), restoring compliance with board composition requirements.
NewTimeSpace News: August 26, 2026, SENSETIME-W(00020.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 2.91 billion, increased by 23.44% YoY.
NewTimeSpace News: August 26, 2026, LUZHU BIOTECH-B(02480.HK) released its Interim Report for the period ended December 31, 2026.
NewTimeSpace News: August 26, 2026, MIDLAND HOLDING(01200.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at HKD 3.31 billion, increased by 31.52% YoY.
NewTimeSpace News: August 26, 2026, CHINACOMSERVICE(00552.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 74.48 billion, decreased by 3.2% YoY.
